Skip to content

Gasex Extract route tablet in dyspepsia.

A comparative clinical study to evaluate the efficacy and safety of Gasex Extract route tablet in the treatment of dyspepsia. - NIL

Status
Recruiting
Phases
Phase 3
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2012/01/002349
Enrollment
60
Registered
2012-01-18
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Dyspepsia

Interventions

Intervention1: Gasex extract route tablet: Dose - 1 tablet twice daily Duration - 4 weeks Frequency - twice daily Route - oral Control Intervention1: Gasex tablet: Dose - 2 tablets twice daily Duratio

Sponsors

The Himalaya Drug Company
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Cases with symptoms of dyspepsia like indigestion, gaseousness, flatulence, abdominal distension & belching. Hematologic and Biochemical parameters within normal limits. Willing to sign inform consent document

Exclusion criteria

Exclusion criteria: Those with serious cardiovascular, cerebrovascular, respiratory, liver or renal disease or any other disorder. The subjects not to have used any drugs, for at least 1 week prior to the study. Subjects with a strong history of food or drug allergy of any kind. Subjects not to have been on weight reducing diets within 3 months prior to the start of the study. No other drugs (including aspirin) to be ingested during the course of the study. Patients unwilling to provide informed consent or abide by the requirements of the study

Design outcomes

Primary

MeasureTime frame
efficacy of Gasex extract route tablet in comparison with Gasex tablet in patients suffering from DyspepsiaTimepoint: 4 weeks

Secondary

MeasureTime frame
safety profile of gasex extract route tabletTimepoint: At 2 weekly intervals for the period of 4 weeks

Countries

India

Contacts

Public ContactDrPralhadSPatki
drnarasimhaswamymandya@gmail.com08232231001

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026